US Insider Trading | Novavax Disclosure of 1 Corporate Insider Transaction on March 9

K-LinePoet · 2026-03-16T14:11:21+00:00

Novavax on 2026 disclosed that executive Kelly James Patrick sold 5,904 shares on March 7, involving an amount of $58,900. Recently, multiple executives and directors have also conducted stock transactions, indicating active trading among company insiders. Novavax is a biopharmaceutical company focused on vaccine development.

K-LinePoet

2026-03-16 14:11:21

Abstract generation in progress

On March 9, 2026, Novavax, Inc. (NVAX) disclosed one insider transaction. Executive Kelly James Patrick sold 5,904 shares on March 7, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 9, 2026	Executive	Kelly James Patrick	March 7, 2026	Sell	5,904	9.98	$58,900
March 5, 2026	Director	Jacobs John C	March 3, 2026	Sell	69,300	9.49	$657,500
March 5, 2026	Executive	Casey Mark J	March 3, 2026	Sell	11,400	9.49	$108,000
March 5, 2026	Executive	O’Hara Elaine	March 3, 2026	Sell	22,400	9.49	$212,900
March 5, 2026	Executive	Draghia-Akli Ruxandra	March 3, 2026	Sell	11,300	9.49	$107,400
March 5, 2026	Executive	Kelly James Patrick	March 3, 2026	Sell	20,900	9.49	$197,900
March 3, 2026	Executive	Kelly James Patrick	March 1, 2026	Sell	28,400	10.14	$287,600
March 3, 2026	Director	Jacobs John C	March 1, 2026	Sell	38,500	10.14	$389,900
March 3, 2026	Executive	Casey Mark J	March 1, 2026	Sell	1,214	10.14	$12,300
March 3, 2026	Executive	O’Hara Elaine	March 1, 2026	Sell	16,300	10.14	$165,700

[Company Profile]

Novavax, Inc., incorporated in Delaware in 1987, is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technologies, including virus-like particles (VLPs) and protein nanoparticle candidate vaccines. Its candidate vaccines are based on genetically engineered three-dimensional nanostructures containing immunologically important proteins. The company’s vaccine pipeline targets multiple infectious diseases, with candidates currently in clinical development for respiratory syncytial virus (RSV), seasonal influenza, and pandemic influenza. Additionally, the company’s joint venture in India, CPL Biologics Private Limited (CPLB), is actively developing multiple candidate vaccines engineered by Novavax.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes